Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In cutaneous melanoma, Anti-Lymphocyte-activation gene 3 (LAG-3) antagonists + Anti-PD-1 antibodies / PD-1 inhibitors currently means relatlimab + nivolumab, an approved checkpoint combination for unresectable or metastatic disease. The key rationale is that LAG-3 and PD-1 are complementary inhibitory pathways on exhausted T cells, so dual blockade can improve antitumor immunity beyond PD-1 inhibition…